Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Rebetron

Executive Summary

Arbitration panel denies Biogen's claims to increased royalties on Rebetron. Biogen maintained increased royalties should be paid under a 1979 licensing agreement for Biogen's alpha interferon patents, because the drug qualified as a combination product, containing Intron A and Rebetol. Biogen indicated that it will continue to receive royalties on Rebetron "in the form of royalties on Intron A"
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel